Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Thyroglobulin mTCR PBL in Metastatic Thyroid Cancer
NCT02390739Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
01
Overview
A Phase 2 trial of Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes in thyroid cancer, sponsored by National Cancer Institute. Planned start Mar 2015; status: withdrawn.
02
Drugs
Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT02390739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390739.